Fiche centre
University of Florida
Gainesville — United States
Essais liés39clinical trials
VilleGainesvillelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06285643
Essais cliniques associés
39| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Eteplirsen | Myopathies | À vérifier | NCT06606340 | EVOLVE — A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice | ENROLLING_BY_INVITATION |
| Cryoneurolysis | Cancer | Non applicable | NCT05444361 | Ultrasound-Guided Percutaneous Cryoneurolysis to Treat Postoperative Pain After Mastectomy | ENROLLING_BY_INVITATION |
| AFSW Guided DOAC | Accident vasculaire cérébral | Phase 3 | NCT05836987 | REACT-AF — The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | RECRUITING |
| AOC 1001 | Myopathies | Phase 1/2 | NCT05027269 | MARINA — Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients | COMPLETED |
| AAV2-GDNF gene therapy | Parkinson | Phase 2 | NCT06285643 | A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD) | ACTIVE_NOT_RECRUITING |
| Lab Assay for seven genetic variants for Parkinson's Disease | Parkinson | À vérifier | NCT04994015 | Parkinson's Foundation PD GENEration Genetic Registry | RECRUITING |
| BBP-418 (ribitol) | Myopathies | Phase 3 | NCT05775848 | Fortify — Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I) | ACTIVE_NOT_RECRUITING |
| AOC 1001 | Myopathies | Phase 2 | NCT05479981 | MARINA-OLE — Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients | COMPLETED |
| Case-Control Study of the Glycotest™ HCC Panel vs AFP for the Detection of Early-stage Hepatocellular Carcinoma | Cancer | À vérifier | NCT03878550 | Case-Control Study of the Glycotest™ HCC Panel vs AFP for the Detection of Early-stage Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING |
| AOC 1001 (del-desiran) | Myopathies | Phase 3 | NCT06411288 | HARBOR — Global Study of Del-desiran for the Treatment of DM1 | COMPLETED |
| VM100 Nutritional Supplement | Myopathies | Phase 2 | NCT07766980 | Evaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy Patients | RECRUITING |
| Emapalumab | Lupus | Phase 3 | NCT05001737 | EMERALD — Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE | COMPLETED |
| NEU-411 | Parkinson | Phase 2 | NCT06680830 | NEULARK — A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease | RECRUITING |
| Anakinra | Épilepsie | Phase 3 | NCT07281027 | COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE" | NOT_YET_RECRUITING |
| Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) | Myopathies | À vérifier | NCT03981575 | Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) | RECRUITING |
| GRASP-01-003 — LGMD R1 Natural History Study | Myopathies | À vérifier | NCT05618080 | GRASP-01-003 — LGMD R1 Natural History Study | ACTIVE_NOT_RECRUITING |
| AIDP — Automated Imaging Differentiation of Parkinsonism | Parkinson | À vérifier | NCT05913687 | AIDP — Automated Imaging Differentiation of Parkinsonism | ACTIVE_NOT_RECRUITING |
| Neuraceq | Alzheimer | À vérifier | NCT05617014 | ADNI4 — Alzheimer's Disease Neuroimaging Initiative 4 | ENROLLING_BY_INVITATION |
| delandistrogene moxeparvovec | Myopathies | Phase 1 | NCT04626674 | ENDEAVOR — A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort | RECRUITING |
| AOC 1020 | Myopathies | Phase 2 | NCT06547216 | FORTITUDE-OLE — Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) | ACTIVE_NOT_RECRUITING |
| AOC 1020 | Myopathies | Phase 1/2 | NCT05747924 | FORTITUDE — Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) | COMPLETED |
| TREAT-MS — Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial | SEP | Non applicable | NCT03500328 | TREAT-MS — Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial | ACTIVE_NOT_RECRUITING |
| Multicenter ALS Imaging Study | Sclérose latérale amyotrophique | À vérifier | NCT06735014 | Multicenter ALS Imaging Study | RECRUITING |
| RGX-202 | Myopathies | Phase 2/3 | NCT05693142 | AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD) | ACTIVE_NOT_RECRUITING |
| PF-06939926 | Myopathies | Phase 3 | NCT04281485 | Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING |
| Del-desiran (AOC 1001) | Myopathies | Phase 3 | NCT07008469 | HARBOR-OLE — Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 | ENROLLING_BY_INVITATION |
| AOC-1020 | Myopathies | Phase 3 | NCT07038200 | FORTITUDE-3 — A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD | RECRUITING |
| Sevasemten 10 mg | Myopathies | Phase 2 | NCT05291091 | Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) | COMPLETED |
| Sevasemten | Myopathies | Phase 2 | NCT06066580 | MESA — Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy | ENROLLING_BY_INVITATION |
| SGT-001 | Myopathies | Phase 1/2 | NCT03368742 | IGNITE DMD — Microdystrophin Gene Transfer Study in Adolescents and Children With DMD | ACTIVE_NOT_RECRUITING |
| Vonsetamig | Lupus | Phase 1 | NCT06975787 | Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis | RECRUITING |
| Litifilimab | Lupus | Phase 2/3 | NCT05531565 | AMETHYST — A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING |
| HBI-002 | Parkinson | Phase 2 | NCT07005180 | LoCaMoTE-PD — Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease | RECRUITING |
| Ofatumumab approved dose | SEP | Phase 3 | NCT06869785 | FILIOS — Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab | ACTIVE_NOT_RECRUITING |
| Remibrutinib oral treatment | SEP | Phase 3 | NCT06846281 | Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | RECRUITING |
| Sevasemten Dose 1 | Myopathies | Phase 2 | NCT06100887 | FOX — Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy | ACTIVE_NOT_RECRUITING |
| Tadalafil | Myopathies | Phase 2/3 | NCT05195775 | Tadalafil as Adjuvant Therapy for DMD | COMPLETED |
| Sacituzumab govitecan-hziy | Cancer | Phase 3 | NCT06486441 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) | ACTIVE_NOT_RECRUITING |
| Zilucoplan | Sclérose latérale amyotrophique | Phase 2/3 | NCT04297683 | HEALEY ALS Platform Trial - Master Protocol | ACTIVE_NOT_RECRUITING |